Michael Vaughn, MD
Addiction Psychiatry · Decatur, GANPI 1598889420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 344 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among addiction psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$735
- Takeda Pharmaceuticals U.S.A., Inc.$724
- Otsuka America Pharmaceutical, Inc.$609
- Johnson & Johnson$476
- Teva Pharmaceuticals USA, Inc.$374
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,07898%
- Education$1482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,332 |
| Lundbeck LLC | 47 | $735 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $724 |
| Otsuka America Pharmaceutical, Inc. | 36 | $609 |
| Johnson & Johnson | 23 | $476 |
| Teva Pharmaceuticals USA, Inc. | 18 | $374 |
| Neurocrine Biosciences, Inc. | 16 | $361 |
| Alkermes, Inc. | 15 | $335 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $313 |
| Vanda Pharmaceuticals Inc. | 11 | $229 |
| Idorsia Pharmaceuticals US Inc | 15 | $171 |
| Axsome Therapeutics, Inc. | 5 | $88 |
| Bausch Health US, LLC | 4 | $83 |
| Eisai Inc. | 5 | $74 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| Shire North American Group Inc | 4 | $56 |
| Orexo US, Inc. | 3 | $51 |
| Corium, LLC | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Indivior Inc. | 2 | $28 |
| Noven Therapeutics, LLC | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
How this compares
$6,227 in reported general payments places this provider in the 95th percentile of 22 addiction psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $81,165 |
| RexultiBrexpiprazole | 15 | $22,036 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 100 | $19,834 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $16,720 |
| VraylarCariprazine Hcl | 12 | $16,617 |
| TrintellixVortioxetine Hydrobromide | 18 | $14,965 |
| BelsomraSuvorexant | 22 | $13,869 |
| Vilazodone Hcl | 45 | $5,568 |
| Quetiapine Fumarate | 243 | $3,346 |
| Oxcarbazepine | 34 | $2,738 |
| Divalproex Sodium ErDivalproex Sodium | 52 | $2,033 |
| Buprenorphine Hcl | 38 | $1,904 |
| Doxepin Hcl | 77 | $1,485 |
| Naltrexone Hcl | 25 | $1,408 |
| Aripiprazole | 114 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $476 | $81,16527 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $609 | $22,03615 claims |
| Indivior Inc.Suboxone | $28 | $16,72024 claims |
| AbbVieVraylar | $1,332 | $16,61712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $724 | $14,96518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 addiction psychiatry providers in Georgia.
Other addiction psychiatry in Decatur
- John MoseriDecatur$1K
- Carmen MartinezDecatur$287
- Michael YoonDecatur$188
- Vinay NagarajSuwanee$9K
- Kambiz AflatoonLawrenceville$4K
- Paige MarnellSavannah$3K
- Ayman FareedDahlonega$2K
- William ColemanAlbany$1K
- Theodore SmithAtlanta$867
- Darvin HegeAtlanta$606
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.